This website contains medical education resources intended solely for Healthcare Professionals (HCPs) practicing within the Asia-Pacific region (excluding mainland China and Japan). The portal is intended for Healthcare Professionals outside the UK and USA. By clicking "Continue" below, you certify that you are a registered Healthcare Professional and wish to access this information for professional purposes. If you are not a Healthcare Professional, please select "Exit" to return to our corporate homepage.

Skip to main content
Are you ready for APAO 2026?

Discover Roche’s Scientific Program and Explore Cutting-Edge Insights!

Hear from leading experts as they discuss the latest faricimab data, translate evidence into clinical practice, and explore real-world insights.

Level up your APAO experience

Attend high-impact Scientific Presentations and browse breakthrough Posters that highlight the latest clinical and scientific advances.

Date

Time 

Indication

Topic

Presenter

Venue

7 Feb

11:50-11:55

DME/DR

Update on Faricimab for Diabetic Macular Edema: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study

Toshinori Murata

N202-203 (L2)

5 Feb

11:05-11:10

DME/DR

Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema at 1 and 2 Years: A Systematic Literature Review and Network Meta-Analysis

Colin Tan

N202-203 (L2)

7 Feb

11:10-11:15

DME/DR

Automated Quantification of Retinal Fluid in Patients with Diabetic Macular Edema: Analysis of Faricimab vs Aflibercept in YOSEMITE/RHINE

Simon Szeto

N202-203 (L2)

5 Feb

17:00-17:05

DME/DR

Predictors of Extended Treatment Interval in DME (Diabetic Macular Edema) Patients Treated With Faricimab in the Phase-3 YOSEMITE/RHINE Trials

Anna Tan

S422 (L4)

7 Feb

16:35-16:40

nAMD/PCV

Four-Year Outcomes of Faricimab in Neovascular Age-Related Macular Degeneration: Safety and Efficacy From the AVONELLE-X Long-Term Extension Trial

Timothy Lai

S422 (L4)

5 Feb

17:40-17:45

nAMD/PCV

Machine Learning–Based 3D Volumetric Analysis of Pigment Epithelial Detachment Reduction With Faricimab vs Aflibercept in TENAYA/LUCERNE

Ling Yeung

S422 (L4)

6 Feb

16:35-16:40

nAMD/PCV

Baseline and Early Treatment Response Variables of Faricimab Durability in Treatment-Naïve nAMD (Neovascular Age-Related Macular Degeneration)

JiHun Song

S428 (L4)

7 Feb

17:15-17:20

nAMD/PCV

Greater Anatomical Improvements With Faricimab vs Aflibercept 8 Weeks After Injections: A TENAYA/LUCERNE Post-Hoc Analysis

Tai-Chi Lin

S422 (L4)

7 Feb

12:00-12:05

nAMD/PCV

Faricimab for Polypoidal Choroidal Vasculopathy: One-Year Results From the Phase-3b/4 SALWEEN Trial

Paisan Rumaviboonsuk

N202-203 (L2)

5 Feb11:25-11:30nAMD/PCVFaricimab for PCV (Polypoidal Choroidal Vasculopathy): One-Year Ethnically Chinese Subgroup Results from Phase-3b/4 SALWEEN TrialMing ZhangN202-203 (L2)
6 Feb11:40-11:45RVOAssociation of Early Macular Leakage Resolution with Extended Dosing Intervals in Patients With RVO (Retinal Vein Occlusion): A Post-Hoc Analysis of the BALATON/COMINO TrialsHemal MehtaS422 (L4)
5 Feb18:05-18:10RWDReal-World Faricimab Outcomes in nAMD (Neovascular Age-Related Macular Degeneration) and DME (Diabetic Macular Edema): The VOYAGER StudyVoraporn ChaikitmongkolS422 (L4)
5 Feb11:10-11:15RWDEffectiveness and Safety of Faricimab in nAMD (Neovascular Age-Related Macular Degeneration) and DME (Diabetic Macular Edema) Eyes Beyond Year-1: UK FARWIDE-nAMD and FARWIDE-DME Study ResultsKenneth FongN202-203 (L2)

Date

Time 

Indication

Topic

Presenter

Venue

5-8 FebAll dayRWDAssessing a 36-Week Refill-Exchange Regimen for Port Delivery Platform With Ranibizumab in Patients With up to 2-Years’ Diagnosis of Neovascular Age-Related Macular Degeneration: Phase-3b Sightspire TrialSeungKyu Lee (Poster)

Post. No

RME-0968

7 Feb15:15-15:20nAMD/DMEImpact of PDS (Port Delivery Platform With Ranibizumab) in Study Eyes vs Anti-VEGF (Vascular Endothelial Growth Factor) in Fellow-Eyes on Efficacy and Safety Outcomes in Bilateral DME (Diabetic Macular Edema) in PagodaYi-Ting HsiehS422 (L4)
6 Feb11:25-11:30nAMD/DMELong-Term Efficacy and Safety of PDS (Port Delivery Platform With Ranibizumab) in Patients With nAMD (Neovascular Age-related Macular Degeneration): Results From the Ladder- and Archway-to-Portal TrialsYuen Yew SenS422 (L4)
6 Feb11:55-12:00nAMD/DMEImpact of the Optimization of Surgical Procedure on the Incidence of Endophthalmitis and Associated Patient Outcomes in Port Delivery Platform with Ranibizumab TrialsSeJoon WooN202-203 (L2)

Date

Time 

Indication

Topic

Presenter

Venue

5 Feb

17:00-17:05

UME

Intraretinal and Subretinal Fluid Resolution With Vamikibart in Uveitic Macular Edema: Phase-1 DOVETAIL Exploratory Results

Iksoo Byon

N209-210 (L2)

5 Feb

17:30-17:35

UME

Interleukin-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Data From Phase-3 MEERKAT and SANDCAT trials

Yih-Shiou Hwang

N209-210 (L2)

Date

Time 

Indication

Topic

Presenter

Venue

5 Feb

09:05-09:10

TED

Primary Results of the Phase-3 SatraGO-1 and SatraGO 2 Trials: Efficacy and Safety of Satralizumab in Thyroid Eye Disease

Dongmei Li

N212 (L2)

Date

Time 

Indication

Topic

Presenter

Venue

5 Feb

11:25-11:30

nAMD/PCV

Faricimab for Polypoidal Choroidal Vasculopathy: One-Year Ethnically Chinese Subgroup Results From Phase-3b/4 SALWEEN Trial

Ming Zhang

N202-203 (L2)

7 Feb17:12-17:18nAMD/PCVReal-World Effectiveness of Faricimab in Chinese Patients With Neovascular Age-Related Macular Degeneration: 3-Month Results From the Farseeing StudyChenjin JinN202-203 (L2)
7 Feb14:30-14:35nAMD/PCVReal-World Short-Term Efficacy Observation of Faricimab in the Treatment of Refractory Wet Macular DegenerationJiantong DuS422 (L4)
7 Feb14:45-14:50nAMD/PCVEfficacy of the Faricimab Loading Regimen in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Real-World Study From ChinaSheng LiS422 (L4)
7 Feb11:12-11:18nAMD/PCV法瑞西单抗治疗新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿以及视网膜静脉阻塞的有效性及安全性真实世界研究Danning LiuN208 (L2)
7 Feb15:20-15:25DME/DRReal-World Evidence on First-Line Treatment Versus Switching to Faricimab for Hyperpermeable Diabetic Macular Edema During Loading PhaseHenan LiuS422 (L4)
5 Feb17:30-17:35DME/DRHigh-Resolution Fluorescein Angiography Generated From Color Fundus Photography Using Deep Learning to Enhance Diabetic Retinopathy Diagnosis and Assessment of Anti-VEGF TherapyRui HuaN202-203 (L2)
6 Feb15:30-15:36nAMD/PCV双抗药物起始联合长效激素治疗 CRVO 引起高度水肿 CME 对比单抗联合激素单中心前瞻性研究观察Zhongyu ZhangS422 (L4)
7 Feb17:54-18:00nAMD/PCVReal-Life Short-Term Experience of Switching From Other Anti-VEGF Therapy to Faricimab in Patients With Refractory Macular Edema Secondary to Retinal Vein Occlusion in ChinaYaoyao SunN202-203 (L2)
7 Feb17:45-18:00nAMD/PCV视网膜中央静脉压对视网膜中央静脉阻塞黄斑水肿抗VEGF治疗的影响Han ZhangS221 (L2)
5 Feb17:35-17:40 Proteome profiling in vitreous reveals the targets and potential signaling pathways of angiopoietin-2Yan ShaoN202-203 (L2)
7 Feb14:30-14:35 Comparison of Intraocular Inflammation Associated With High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality AnalysisJiantong DuS422 (L4)
8 Feb11:35-11:40 Carotid Revascularization and Circle of Willis in Ocular Ischemic Syndrome: Association With Neovascular Glaucoma and Visual PrognosisJialin WangS425 (L4)
5 Feb11:40-11:48 糖尿病视网膜神经血管单元与小胶质细胞Zizhong HuS228 (L2)
Speakers
A Winning Strategy - Advancing Treatment Outcomes with Faricimab in nAMD and DME

6th February 2026 | 13:00 - 14:00 HKT

Chancellor Room, HKCEC

Add to Calendar
APAC Panorama - Doing Now What Patients Need Next

6th February 2026 | Registration begins: 6:30 PM

Concord Room - Renaissance Harbour View Hotel, Hong Kong

Register to panorama evening event
Macula Matters Podcast
Episode 1: SALWEEN 1-Year Insights: Redefining PCV Care

A/Prof. Adrian Koh is joined by leading expert Prof. Gemmy Cheung to dissect the critical 1-year results from the SALWEEN study. This podcast is a deep dive into the 1-year SALWEEN data readout, focusing on the implications for patients with PCV. The experts analyze the key clinical takeaways from the SALWEEN data, discussing its impact on clinical treatment paradigms for PCV patients.

SALWEEN 1-Year Insights: Redefining PCV Care

Contact Us
Learn More

This meeting is intended for healthcare professionals outside the UK and USA.

Restricted

Bookmarking is available only for logged-in users.

Sign up Log in